

IN THE CLAIMS:

Please amend the claims as follows:

1. (Currently Amended) Use of a ligand for fibrinogen and/or fibrin for producing an agent for the in vitro treatment and/or prophylaxis of microcirculatory disorders and/or for influencing the rheology of a mammal.

2. (Original) Use according to claim 1, characterized in that the ligand is a peptide preferably having 3 to 10 amino acids.

3. (Original) Use according to claim 2, characterized in that the peptide contains the following amino acid sequence:

Gly-Pro-Arg-Pro-x

4. (Original) Use according to claim 3, characterized in that the peptide has the following amino acid sequence:

Gly-Pro-Arg-Pro-Lys

5. (Original) Use according to claim 1, characterized in that the ligand is an antibody.

6. (Currently Amended) Use according to ~~any one of claims~~ claim 1 to 5, characterized in that the mammal is a human being.

7. (Currently Amended) Use according to ~~any one of claims~~ claim 1 to 6, characterized in that the ligand is selected from polyclonal and monoclonal anti-fibrinogen antibodies and anti-fibrin antibodies.

8. (Currently Amended) Use according to ~~any one of claims~~ claim 1 to 7, characterized in that the ligand in the agent is bound to a solid matrix.

9. (Original) Use according to claim 8, characterized in that the matrix is selected from glass, carbohydrates, polymethacrylates and polyamides.

10. (Original) Use according to claim 9, characterized in that the matrix is Sepharose.

11. (Currently Amended) Use according to ~~any one of claims~~ claim 8 to 40, characterized in that the matrix consists of beads, fibers and/or a membrane.

12. (Currently Amended) Use according to ~~any one or several of the aforementioned claims~~ claim 8, characterized in that the microcirculatory disorder appears in connection with diabetes, retinopathy, polyneuropathy, apoplexy, sudden deafness, sepsis, arterial occlusive diseases and/or impaired kidney function.

13. (Original) Adsorber column containing a matrix and a ligand, wherein said ligand has a specificity for fibrin and/or fibrinogen.

14. (Currently Amended) Adsorber column according to claim 13, wherein the ligand is the a peptide as indicated in any one of claims 3 or 4 containing the amino acid sequence: Gly-Pro-Arg-Pro-x wherein x can be any desired amino acid or spacer, or wherein the ligand is a peptide having the amino acid sequence Gly-Pro-Arg-Pro-Lys.

15. (Currently Amended) Adsorber column according to claim 13 ~~or 14~~, wherein the matrix is Sepharose.

16. (Currently Amended) Method for influencing the microcirculation of a mammal, wherein blood of the mammal is passed *in vitro* over the column according to claim 13, ~~14 or 15~~.

17. (Original) Method according to claim 16, characterized in that it is carried out as an apheresis method for plasma or whole blood.

18. (Currently Amended) Pharmaceutical compositions containing a ligand for fibrinogen and/or fibrin, wherein the ligand is a peptide having 3 to 10 amino acids.